Prolong Pharmaceuticals Raises $30M in Funding

Prolong Pharmaceuticals, a South Plainfield, New Jersey-based company that develops biopharmaceutical products targeting the treatment of anemia resulting from an oxygen deficiency, received a commitment of $30m in funding from a private investor group.
The capital will enable the company to continue its research and development efforts and clinical programs for SANGUINATE™, a novel oxygen transfer agent.
Commenting on the funding, Prolong President Glenn Kazo said: “Over the coming months we will be focused on developing sufficient manufacturing capacity to supply our clinical development needs, researching additional indications, and expanding the infrastructure we expect to require as we move forward with SANGUINATE(TM)”.

Join the discussion